Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.

ABSTRACT:

Purpose

New prognostic markers to guide treatment decisions in early stage non-small cell lung cancer are necessary to improve patient outcomes. In this report, we assess the utility of a predefined mRNA expression signature of cell-cycle progression genes (CCP score) to define 5-year risk of lung cancer-related death in patients with early stage lung adenocarcinoma.

Experimental design

A CCP score was calculated from the mRNA expression levels of 31 proliferation genes in stage I and stage II tumor samples from two public microarray datasets [Director's Consortium (DC) and GSE31210]. The same gene set was tested by quantitative PCR in 381 formalin-fixed paraffin-embedded (FFPE) primary tumors. Association of the CCP score with outcome was assessed by Cox proportional hazard

SUBMITTER: Wistuba II 

PROVIDER: S-EPMC3834029 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature